Covered recipient · General Payments record
LINNEA I CHAP
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$55,329.76
139 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,715.00 | 6 |
| Travel and Lodging | $10,297.18 | 13 |
| Consulting Fee | $5,900.00 | 4 |
| Honoraria | $4,250.00 | 3 |
| Food and Beverage | $3,136.65 | 111 |
| Education | $30.93 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Seagen Inc. | $32,623.78 | 20 |
| Genentech USA, Inc. | $6,876.98 | 19 |
| PFIZER INC. | $6,195.85 | 6 |
| AstraZeneca Pharmaceuticals LP | $3,901.31 | 16 |
| Novartis Pharmaceuticals Corporation | $2,360.07 | 4 |
| MACROGENICS, INC. | $1,500.00 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $416.93 | 15 |
| Amgen Inc. | $316.22 | 9 |
| PUMA BIOTECHNOLOGY, INC. | $158.29 | 7 |
| GENZYME CORPORATION | $137.01 | 8 |
| Lilly USA, LLC | $116.73 | 1 |
| Pharmacyclics LLC, An AbbVie Company | $86.64 | 4 |
| Gilead Sciences, Inc. | $63.15 | 3 |
| Exelixis Inc. | $58.29 | 2 |
| Daiichi Sankyo Inc. | $50.00 | 2 |
| Eisai Inc. | $48.51 | 2 |
| Acrotech Biopharma LLC | $45.00 | 3 |
| Merck Sharp & Dohme Corporation | $43.74 | 2 |
| Incyte Corporation | $43.50 | 2 |
| JAZZ PHARMACEUTICALS INC. | $41.95 | 2 |
| Blueprint Medicines Corporation | $41.58 | 2 |
| BeiGene USA, Inc. | $33.60 | 1 |
| Celgene Corporation | $25.00 | 1 |
| TerSera Therapeutics LLC | $24.24 | 1 |
| Myovant Sciences Inc. | $22.28 | 1 |
| EMD Serono, Inc. | $21.61 | 1 |
| Global Blood Therapeutics, Inc. | $19.75 | 1 |
| Taiho Oncology, Inc. | $19.75 | 1 |
| TG THERAPEUTICS, INC. | $19.75 | 1 |
| Dova Pharmaceuticals | $18.25 | 1 |
Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LINNEA I CHAP
NPI 1700839362 · CMS profile ID 77578
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
BEVERLY HILLS, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1700839362?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LINNEA I CHAP, NPI 1700839362, CMS profile ID 77578. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700839362?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). LINNEA I CHAP, NPI 1700839362, CMS profile ID 77578. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700839362?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- LINNEA I CHAP, NPI 1700839362, CMS profile ID 77578, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1700839362?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
139 matching records · $55,329.76 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–139 of 139.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $19.75 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789069231 | CMS |
| PFIZER INC. | $1,500.00 | 05/14/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833394103 | CMS |
| Merck Sharp & Dohme Corporation | $19.05 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848677503 | CMS |
| Merck Sharp & Dohme Corporation | $24.69 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848706895 | CMS |
| Genentech USA, Inc. | $23.25 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835941793 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.16 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829540055 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $20.25 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789079621 | CMS |
| JAZZ PHARMACEUTICALS INC. | $19.87 | 05/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845589609 | CMS |
| GENZYME CORPORATION | $13.37 | 04/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843464835 | CMS |
| Amgen Inc. | $25.64 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825557717 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $25.00 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834086013 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.00 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830095231 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $20.00 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789149119 | CMS |
| Daiichi Sankyo Inc. | $25.00 | 04/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836281165 | CMS |
| Gilead Sciences, Inc. | $26.54 | 04/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848174645 | CMS |
| Genentech USA, Inc. | $22.00 | 03/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835941753 | CMS |
| Exelixis Inc. | $30.38 | 03/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838867541 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $24.39 | 03/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834086293 | CMS |
| Amgen Inc. | $25.64 | 03/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825557713 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.25 | 03/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829783363 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $17.03 | 03/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789057575 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $20.84 | 03/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781008817 | CMS |
| Acrotech Biopharma LLC | $15.00 | 03/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855378813 | CMS |
| Genentech USA, Inc. | $19.53 | 03/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835941791 | CMS |
| MACROGENICS, INC. | $1,500.00 | 03/03/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833897687 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.00 | 02/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829560191 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $20.00 | 02/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789064683 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $29.85 | 02/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834094251 | CMS |
| GENZYME CORPORATION | $12.49 | 02/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843464831 | CMS |
| Genentech USA, Inc. | $24.38 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835941787 | CMS |
| Genentech USA, Inc. | $22.00 | 02/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835941773 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $21.04 | 01/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781008815 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $24.40 | 01/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834092463 | CMS |
| AstraZeneca Pharmaceuticals LP | $25.00 | 01/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829576357 | CMS |
| JAZZ PHARMACEUTICALS INC. | $22.08 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845577339 | CMS |
| Exelixis Inc. | $27.91 | 01/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838865985 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $19.75 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789194295 | CMS |
| Genentech USA, Inc. | $19.44 | 01/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835941783 | CMS |
| BeiGene USA, Inc. | $33.60 | 01/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846699339 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,002,595.80 | 174 |
| PY2024 | Principal investigator | $713,766.70 | 102 |
| PY2023 | Recipient | $300.00 | 1 |
| PY2023 | Principal investigator | $117,471.27 | 9 |
| PY2022 | Recipient | $450.00 | 1 |
| PY2022 | Principal investigator | $936,160.90 | 31 |
| PY2021 | Principal investigator | $1,175,372.54 | 30 |
| PY2020 | Recipient | $1,068.14 | 2 |
| PY2020 | Principal investigator | $856,898.96 | 10 |
| PY2019 | Recipient | $6,415.35 | 2 |
| PY2019 | Principal investigator | $477,327.84 | 6 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
174 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $111,014.15 | 12/31/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center | A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Follow | No dispute reported | 06/30/2026 | 1232924246 |
| Principal investigator 1 | Genentech, Inc. | $7,440.00 | 12/19/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579363 |
| Principal investigator 1 | Genentech, Inc. | $690.00 | 12/19/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579366 |
| Principal investigator 1 | Genentech, Inc. | $10,880.00 | 12/19/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579369 |
| Principal investigator 1 | BioNTech SE | $195.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249017873 |
| Principal investigator 1 | BioNTech SE | $195.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249017875 |
| Principal investigator 1 | BioNTech SE | $1,857.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249017877 |
| Principal investigator 1 | BioNTech SE | $1,857.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249017879 |
| Principal investigator 1 | BioNTech SE | $1,857.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249017881 |
| Principal investigator 1 | BioNTech SE | $1,857.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249017883 |
| Principal investigator 1 | BioNTech SE | $98.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249018073 |
| Principal investigator 1 | BioNTech SE | $98.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249018075 |
| Principal investigator 1 | BioNTech SE | $98.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249018077 |
| Principal investigator 1 | BioNTech SE | $98.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249018079 |
| Principal investigator 1 | BioNTech SE | $165.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249018081 |
| Principal investigator 1 | BioNTech SE | $165.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249018083 |
| Principal investigator 1 | BioNTech SE | $165.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249018085 |
| Principal investigator 1 | BioNTech SE | $165.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249018087 |
| Principal investigator 1 | BioNTech SE | $195.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249018089 |
| Principal investigator 1 | BioNTech SE | $195.00 | 11/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327 | No dispute reported | 06/30/2026 | 1249018091 |
| Principal investigator 1 | Genentech, Inc. | $232.00 | 10/29/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579320 |
| Principal investigator 1 | Genentech, Inc. | $10,350.00 | 10/29/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579325 |
| Principal investigator 1 | Genentech, Inc. | $300.84 | 10/29/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579329 |
| Principal investigator 1 | Genentech, Inc. | $232.00 | 10/29/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579332 |
| Principal investigator 1 | Genentech, Inc. | $7,547.30 | 10/29/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579337 |
| Principal investigator 1 | Genentech, Inc. | $52.00 | 10/29/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579341 |
| Principal investigator 1 | Genentech, Inc. | $169.00 | 10/29/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579346 |
| Principal investigator 1 | Genentech, Inc. | $311.00 | 10/29/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579351 |
| Principal investigator 1 | Genentech, Inc. | $255.00 | 10/29/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579355 |
| Principal investigator 1 | Genentech, Inc. | $311.00 | 10/29/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579358 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $111.72 | 10/28/2025 | Non-covered Recipient Entity BEVERLY HILLS CANCER CENTER | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190307251 |
| Principal investigator 1 | Genentech, Inc. | $232.00 | 09/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579252 |
| Principal investigator 1 | Genentech, Inc. | $311.00 | 09/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579257 |
| Principal investigator 1 | Genentech, Inc. | $424.00 | 09/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579301 |
| Principal investigator 1 | Genentech, Inc. | $86.00 | 08/26/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579248 |
| Principal investigator 1 | BioNTech SE | $74.00 | 08/25/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center & Optima Diagnostic Imaging | BNT323-03 | No dispute reported | 06/30/2026 | 1249017486 |
| Principal investigator 1 | Genentech, Inc. | $232.00 | 08/21/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579261 |
| Principal investigator 1 | Genentech, Inc. | $104.00 | 08/21/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579265 |
| Principal investigator 1 | Genentech, Inc. | $938.50 | 08/21/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579271 |
| Principal investigator 1 | Genentech, Inc. | $415.00 | 08/21/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579280 |
| Principal investigator 1 | PFIZER INC. | $7,750.00 | 07/19/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TACTIVEU AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 AND OLDER WITH ER ADVANCED OR METASTATIC BREAST CANCER SUBSTUDY C ARV471 IN COMBINATION WITH SAMURACICLIB | No dispute reported | 06/30/2026 | 1228782689 |
| Principal investigator 1 | BioNTech SE | $420.00 | 07/09/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center & Optima Diagnostic Imaging | BNT323-03 | No dispute reported | 06/30/2026 | 1249017484 |
| Principal investigator 1 | Genentech, Inc. | $424.00 | 07/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579276 |
| Principal investigator 1 | Genentech, Inc. | $311.00 | 07/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579282 |
| Principal investigator 1 | Genentech, Inc. | $208.00 | 07/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579286 |
| Principal investigator 1 | Genentech, Inc. | $10,880.00 | 07/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579292 |
| Principal investigator 1 | Genentech, Inc. | $232.00 | 07/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579296 |
| Principal investigator 1 | Genentech, Inc. | $690.00 | 07/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579304 |
| Principal investigator 1 | Genentech, Inc. | $277.00 | 07/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579307 |
| Principal investigator 1 | Genentech, Inc. | $232.00 | 07/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579311 |
| Principal investigator 1 | Genentech, Inc. | $311.00 | 07/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579317 |
| Principal investigator 1 | BioNTech SE | $97.00 | 07/01/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center & Optima Diagnostic Imaging | BNT327-02 | No dispute reported | 06/30/2026 | 1249017482 |
| Principal investigator 1 | BioNTech SE | $97.00 | 07/01/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center & Optima Diagnostic Imaging | BNT327-02 | No dispute reported | 06/30/2026 | 1249017502 |
| Principal investigator 1 | PFIZER INC. | $6,875.00 | 06/26/2025 | Non-covered Recipient Entity Beverly Hills Oncology Medical Group Inc | TACTIVEU AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B2 OPENLABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY PK AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT ARV471PF07850327 AN ORAL PROTEOLYSIS TARGETING CHIMERA IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 AND OLDER WITH ER ADVANCED OR METASTATIC BREAST CANCER SUBSTUDY C ARV471 IN COMBINATION WITH SAMURACICLIB | No dispute reported | 06/30/2026 | 1228789942 |
| Principal investigator 1 | Genentech, Inc. | $1,860.00 | 06/12/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579209 |
| Principal investigator 1 | BioNTech SE | $336.00 | 05/15/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018015 |
| Principal investigator 1 | BioNTech SE | $1,784.00 | 05/15/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018017 |
| Principal investigator 1 | BioNTech SE | $195.00 | 05/15/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018019 |
| Principal investigator 1 | BioNTech SE | $336.00 | 05/15/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018049 |
| Principal investigator 1 | BioNTech SE | $1,784.00 | 05/15/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018051 |
| Principal investigator 1 | BioNTech SE | $195.00 | 05/15/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018053 |
| Principal investigator 1 | BioNTech SE | $336.00 | 05/15/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018055 |
| Principal investigator 1 | BioNTech SE | $1,784.00 | 05/15/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018057 |
| Principal investigator 1 | BioNTech SE | $195.00 | 05/15/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018059 |
| Principal investigator 1 | Genentech, Inc. | $3,720.00 | 05/08/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579238 |
| Principal investigator 1 | BioNTech SE | $97.00 | 05/01/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center & Optima Diagnostic Imaging | BNT327-02 | No dispute reported | 06/30/2026 | 1249017480 |
| Principal investigator 1 | BioNTech SE | $97.00 | 05/01/2025 | Non-covered Recipient Entity Beverly Hills Cancer Center & Optima Diagnostic Imaging | BNT327-02 | No dispute reported | 06/30/2026 | 1249017500 |
| Principal investigator 1 | Eli Lilly and Company | $1,492.00 | 04/29/2025 | Non-covered Recipient Entity BEVERLY HILLS CANCER CENTER | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187881250 |
| Principal investigator 1 | Genentech, Inc. | $311.00 | 04/28/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579234 |
| Principal investigator 1 | Genentech, Inc. | $348.00 | 04/28/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579241 |
| Principal investigator 1 | Genentech, Inc. | $424.00 | 04/28/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579245 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,592.48 | 04/25/2025 | Non-covered Recipient Entity HIGHLAND MEDICAL HEMATOLOGY AND ONCOLOGY | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185542436 |
| Principal investigator 1 | BioNTech SE | $336.00 | 04/22/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018021 |
| Principal investigator 1 | BioNTech SE | $1,784.00 | 04/22/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018023 |
| Principal investigator 1 | BioNTech SE | $195.00 | 04/22/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018025 |
| Principal investigator 1 | BioNTech SE | $336.00 | 04/22/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018061 |
| Principal investigator 1 | BioNTech SE | $1,784.00 | 04/22/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018063 |
| Principal investigator 1 | BioNTech SE | $195.00 | 04/22/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018065 |
| Principal investigator 1 | BioNTech SE | $336.00 | 04/22/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018067 |
| Principal investigator 1 | BioNTech SE | $1,784.00 | 04/22/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018069 |
| Principal investigator 1 | BioNTech SE | $195.00 | 04/22/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018071 |
| Principal investigator 1 | BioNTech SE | $97.00 | 04/15/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018007 |
| Principal investigator 1 | Genentech, Inc. | $690.00 | 04/15/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579214 |
| Principal investigator 1 | Genentech, Inc. | $10,880.00 | 04/15/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579218 |
| Principal investigator 1 | BioNTech SE | $13,924.00 | 04/10/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018003 |
| Principal investigator 1 | BioNTech SE | $690.00 | 04/10/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018005 |
| Principal investigator 1 | BioNTech SE | $90.00 | 04/10/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018009 |
| Principal investigator 1 | BioNTech SE | $559.00 | 04/10/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018011 |
| Principal investigator 1 | BioNTech SE | $138.00 | 04/10/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018013 |
| Principal investigator 1 | BioNTech SE | $90.00 | 04/10/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018045 |
| Principal investigator 1 | BioNTech SE | $90.00 | 04/10/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018047 |
| Principal investigator 1 | BioNTech SE | $13,924.00 | 04/01/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017999 |
| Principal investigator 1 | BioNTech SE | $690.00 | 04/01/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018001 |
| Principal investigator 1 | Genentech, Inc. | $232.00 | 04/01/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579202 |
| Principal investigator 1 | Genentech, Inc. | $104.00 | 04/01/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579206 |
| Principal investigator 1 | Genentech, Inc. | $311.00 | 04/01/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579222 |
| Principal investigator 1 | Genentech, Inc. | $349.00 | 04/01/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579231 |
| Principal investigator 1 | BioNTech SE | $8,905.30 | 03/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017913 |
| Principal investigator 1 | BioNTech SE | $614.00 | 03/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017985 |
| Principal investigator 1 | BioNTech SE | $1,068.00 | 03/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017987 |
| Principal investigator 1 | BioNTech SE | $90.00 | 03/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017989 |
| Principal investigator 1 | BioNTech SE | $173.00 | 03/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017991 |
| Principal investigator 1 | BioNTech SE | $930.00 | 03/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017993 |
| Principal investigator 1 | BioNTech SE | $918.00 | 03/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017995 |
| Principal investigator 1 | BioNTech SE | $59.00 | 03/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017997 |
| Principal investigator 1 | BioNTech SE | $90.00 | 03/25/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018043 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15,864.00 | 03/25/2025 | Non-covered Recipient Entity BEVERLY HILLS CANCER CENTER | A phase II multicenter open label two cohort non comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant hormone receptor HR positive HER2 negative advanced breast cancer aBC who have p | No dispute reported | 06/30/2026 | 1190308788 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,007.90 | 03/19/2025 | Non-covered Recipient Entity BEVERLY HILLS CANCER CENTER | A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy | No dispute reported | 06/30/2026 | 1185542442 |
| Principal investigator 1 | BioNTech SE | $7,851.75 | 03/14/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017911 |
| Principal investigator 1 | BioNTech SE | $3,003.90 | 03/11/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017909 |
| Principal investigator 1 | Genentech, Inc. | $311.00 | 03/11/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579161 |
| Principal investigator 1 | Genentech, Inc. | $479.50 | 03/11/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579170 |
| Principal investigator 1 | Genentech, Inc. | $231.92 | 03/11/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579182 |
| Principal investigator 1 | Genentech, Inc. | $566.00 | 03/11/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579185 |
| Principal investigator 1 | Genentech, Inc. | $208.00 | 03/06/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579157 |
| Principal investigator 1 | Genentech, Inc. | $311.00 | 03/06/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579174 |
| Principal investigator 1 | Genentech, Inc. | $10,880.00 | 03/06/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579178 |
| Principal investigator 1 | Genentech, Inc. | $690.00 | 03/06/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579189 |
| Principal investigator 1 | Genentech, Inc. | $347.92 | 03/06/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579193 |
| Principal investigator 1 | Genentech, Inc. | $52.00 | 03/06/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579198 |
| Principal investigator 1 | BioNTech SE | $8,780.85 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017907 |
| Principal investigator 1 | BioNTech SE | $345.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017961 |
| Principal investigator 1 | BioNTech SE | $357.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017963 |
| Principal investigator 1 | BioNTech SE | $310.50 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017965 |
| Principal investigator 1 | BioNTech SE | $1,262.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017967 |
| Principal investigator 1 | BioNTech SE | $497.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017969 |
| Principal investigator 1 | BioNTech SE | $586.50 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017971 |
| Principal investigator 1 | BioNTech SE | $656.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017973 |
| Principal investigator 1 | BioNTech SE | $59.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017975 |
| Principal investigator 1 | BioNTech SE | $90.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017977 |
| Principal investigator 1 | BioNTech SE | $150.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017979 |
| Principal investigator 1 | BioNTech SE | $629.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017981 |
| Principal investigator 1 | BioNTech SE | $930.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017983 |
| Principal investigator 1 | BioNTech SE | $90.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018039 |
| Principal investigator 1 | BioNTech SE | $90.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018041 |
| Principal investigator 1 | Genentech, Inc. | $1,860.00 | 03/04/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579166 |
| Principal investigator 1 | BioNTech SE | $7,976.20 | 02/18/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017905 |
| Principal investigator 1 | BioNTech SE | $1,035.00 | 02/13/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017949 |
| Principal investigator 1 | BioNTech SE | $90.00 | 02/13/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017951 |
| Principal investigator 1 | BioNTech SE | $1,386.00 | 02/13/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017953 |
| Principal investigator 1 | BioNTech SE | $838.00 | 02/13/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017955 |
| Principal investigator 1 | BioNTech SE | $13,924.00 | 02/13/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017957 |
| Principal investigator 1 | BioNTech SE | $690.00 | 02/13/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017959 |
| Principal investigator 1 | BioNTech SE | $90.00 | 02/13/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018033 |
| Principal investigator 1 | BioNTech SE | $90.00 | 02/13/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018035 |
| Principal investigator 1 | BioNTech SE | $90.00 | 02/13/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018037 |
| Principal investigator 1 | BioNTech SE | $12,269.25 | 02/05/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017903 |
| Principal investigator 1 | Genentech, Inc. | $14,248.00 | 02/05/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211579226 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,522.75 | 01/31/2025 | Non-covered Recipient Entity BEVERLY HILLS CANCER CENTER | A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) | No dispute reported | 06/30/2026 | 1185542440 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $847.86 | 01/31/2025 | Non-covered Recipient Entity BEVERLY HILLS CANCER CENTER | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190307253 |
| Principal investigator 1 | BioNTech SE | $7,976.20 | 01/21/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017901 |
| Principal investigator 1 | BioNTech SE | $345.00 | 01/17/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017933 |
| Principal investigator 1 | BioNTech SE | $131.10 | 01/17/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017935 |
| Principal investigator 1 | BioNTech SE | $1,765.02 | 01/17/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017937 |
| Principal investigator 1 | BioNTech SE | $310.50 | 01/17/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017939 |
| Principal investigator 1 | BioNTech SE | $463.68 | 01/17/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017941 |
| Principal investigator 1 | BioNTech SE | $1,083.30 | 01/17/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017943 |
| Principal investigator 1 | BioNTech SE | $930.00 | 01/17/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017947 |
| Principal investigator 1 | BioNTech SE | $131.10 | 01/17/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018027 |
| Principal investigator 1 | BioNTech SE | $11,909.20 | 01/17/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018095 |
| Principal investigator 1 | AstraZeneca UK Limited | $576,284.10 | 01/14/2025 | Non-covered Recipient Entity BEVERLY HILLS CANCER CENTER | CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 | No dispute reported | 06/30/2026 | 1185542438 |
| Principal investigator 1 | BioNTech SE | $483.00 | 01/09/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017915 |
| Principal investigator 1 | BioNTech SE | $138.00 | 01/09/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017917 |
| Principal investigator 1 | BioNTech SE | $90.00 | 01/09/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017919 |
| Principal investigator 1 | BioNTech SE | $150.00 | 01/09/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017921 |
| Principal investigator 1 | BioNTech SE | $842.00 | 01/09/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017945 |
| Principal investigator 1 | BioNTech SE | $138.00 | 01/09/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018029 |
| Principal investigator 1 | BioNTech SE | $90.00 | 01/09/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018031 |
| Principal investigator 1 | BioNTech SE | $2,451.08 | 01/07/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017923 |
| Principal investigator 1 | BioNTech SE | $463.68 | 01/07/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017925 |
| Principal investigator 1 | BioNTech SE | $90.00 | 01/07/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017927 |
| Principal investigator 1 | BioNTech SE | $680.00 | 01/07/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017929 |
| Principal investigator 1 | BioNTech SE | $150.00 | 01/07/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249017931 |
| Principal investigator 1 | BioNTech SE | $8,592.75 | 01/07/2025 | Non-covered Recipient Entity BEVERLY HILLS ONCOLOGY MEDICAL GROUP INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249018093 |